



SGLT2 inhibitors in Chronic Kidney Disease: Innovation after 20 years



An LSNH Educational Event in Collaboration with AstraZeneca

Moderator: Ali Abu-Alfa, MD



Prof. David Wheeler, FCRP, MBCHB, MD
Professor of Kidney Medicine
Head of Clinical Research (UCLMC) University College
London Medical School
Chairman of Nominating Committee of the
Kidney Disease: Improving Global Outcomes (KDIGO)



Prof. Ali Abu-Alfa, MD, FASN, FAHA
Professor of Medicine
Head, Division of Nephrology and Hypertension
American University of Beirut
President, Lebanese Society of Nephrology and Hypertension
Chair-elect, International Society of Nephrology - Middle East

March 25, 2021

SGLT2 inhibitors in CKD: Innovation after 20 years

Topic	Presenter	Time
Welcome & Introduction	Prof. Ali Abu-Alfa	5 min
Burden of Cardio Renal Disease	Prof. Ali Abu-Alfa	10 min
CVOT: The DECLARE TIMI-58 Trial	Prof. Ali Abu-Alfa	15 min
DAPA CKD Trial Results	Prof. David Wheeler	20 min
Early interventions to improve CKD outcomes, practical recommendations and case studies	Prof. David Wheeler	15 min
Q &A	All	25 min



Prof. David Wheeler

Prof. David Wheeler is a Professor of Kidney Medicine at the University College London Medical School.

He is also the Head of Clinical Research and is an Honorary Consultant Nephrologist at Royal Free London National Health Service Foundation Trust.

In addition, he is an Honorary Professorial Fellow at the George Institute for Global Health.

He is the Chairman of Nominating Committee of the Kidney Disease: Improving Global Outcomes (KDIGO). Furthermore, he is an Advancing Clinical Trials Group member of the International Society of Nephrology. He is also a Committee member of the UK Renal Trials Network (UKRTN). He is also a member of the UK Renal Registry (UKRR) and the Renal Association.

He is an Editorial Board member of BMC Medicine and Current Opinion in Nephrology and Hypertension. Moreover, he is a reviewer for the American Journal of Kidney Diseases, BMC Public Health and Sensors.

He has received the International Distinguished Medal from the National Kidney Foundation (NKF) (2011). Additionally, he is a consultant and serves on the speakers' bureau for Amgen, Janssen, Napp Pharmaceuticals, Merck, Mundipharma and Vifor Pharma.

Prof. Wheeler's research interests focus on complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid lowering regimens, calcimimetics and sodium glucose cotransporter 2 inhibitors in patients chronic kidney disease.



Prof. Ali Abu-Alfa

Prof. Ali Abu-Alfa is a Professor of Medicine, and Head of the Division of Nephrology and Hypertension at the American University of Beirut (AUB).

He is the Director for the Human Research Protection Program at AUB, and for Research Affairs at AUB Medical Center.

He joined AUB in 2010 after spending 2 decades at the Yale School of Medicine in New Haven, CT, USA, and remains an Adjunct faculty member at Yale in the Section of Nephrology.



He earned his MD degree from AUB in 1985, completed a residency in Internal Medicine at Northwestern in 1990 and a fellowship in Nephrology at Yale in 1993. He is board-certified by the American Board of Internal Medicine-Nephrology, is a certified hypertension specialist (AHSCP) and a Fellow of the American Heart Association and member of its hypertension council.

In December 2014, he launched and is serving as founding President of the Middle East Chapter of the International Society for Peritoneal Dialysis. He is currently the President for the Lebanese Society of Nephrology and Hypertension.

He is the Chair-Elect of the International Society of Nephrology (ISN)-Middle East Regional Board and is serving as an ISN council member. He is a former member of the ISN Dialysis Committee and current member of the Continuous Medical Education Committee and Renal Disaster Committee of the ISN. He completed a 3 years term as member of the KDIGO Executive committee in Dec 2018.

In addition to his strong engagement in these regional and international nephrology circles, Dr Abu-Alfa's continues to pursue his scientific interests in the areas of Peritoneal Dialysis, Chronic Kidney Disease (CKD), complex hypertension, Mineral and Bone Disorder in CKD, imaging issues in kidney patients including Nephrogenic Systemic Fibrosis and use of Gadolinium Based Contrast Agents. He is also very active in the sphere of research ethics, its regulatory and administrative frameworks, and protection of human subjects in research.

